¶ BRD4 (Bromodomain-Containing Protein 4)
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
| Full Name | Bromodomain-Containing Protein 4 |
| Gene Symbol | BRD4 |
| Chromosomal Location | 19p13.12 |
| NCBI Gene ID | [23476](https://www.ncbi.nlm.nih.gov/gene/23476) |
| OMIM | [608749](https://omim.org/entry/608749) |
| Ensembl | [ENSG00000141867](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141867) |
| UniProt | [O60885](https://www.uniprot.org/uniprot/O60885) |
| Protein | Bromodomain-containing protein 4 |
| Associated Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Huntington's disease](/diseases/huntingtons-disease), neuroinflammation |
BDNF is a human gene. Variants in BDNF have been implicated in Alzheimer's Disease, Parkinson's Disease, Huntington's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
BRD4 encodes a member of the bromodomain and extra-terminal domain (BET) protein family that functions as an epigenetic reader of acetylated histones and a master regulator of transcriptional elongation. BRD4 contains two tandem bromodomains (BD1 and BD2) that recognize acetylated lysine residues on histones H3 and H4, as well as an extra-terminal (ET) domain that recruits transcriptional regulators.
BRD4 plays essential roles in gene regulation through several mechanisms:
- Transcriptional elongation: BRD4 recruits the positive transcription elongation factor b (P-TEFb/CDK9) to acetylated chromatin, stimulating RNA Polymerase II elongation and releasing promoter-proximal pausing at thousands of genes
- Super-enhancer regulation: BRD4 is disproportionately concentrated at super-enhancers — large clusters of enhancers that drive cell-identity genes. In neurons, super-enhancers control BDNF, synaptic receptor genes, and ion channel genes
- Inflammatory gene activation: BRD4 is recruited to NF-κB-responsive promoters during inflammation, serving as a co-activator for pro-inflammatory transcription
- Bookmarking during mitosis: BRD4 remains bound to acetylated chromatin during mitosis, "bookmarking" active genes for rapid reactivation after cell division
- Phase separation: BRD4 undergoes liquid-liquid phase separation to form transcriptional condensates at super-enhancers, concentrating transcriptional machinery
In the brain, BRD4 is essential for activity-dependent gene expression, synaptic plasticity, and learning/memory formation.
BRD4 is aberrantly upregulated in AD brain, particularly in microglia and astrocytes, where it drives neuroinflammatory transcription:
- NF-κB-dependent inflammation: BRD4 is required for sustained NF-κB transcriptional activity; it binds acetylated RelA/p65 and recruits P-TEFb to inflammatory gene promoters including TNF, IL-6, IL-1β, and complement components
- Amyloid-driven BRD4 activation: Amyloid-β oligomers activate BRD4 through NF-κB and p38-MAPK signaling, creating a feed-forward inflammatory loop
- Tau-related epigenetic dysregulation: Pathological tau disrupts nuclear BRD4 distribution, altering super-enhancer landscapes and gene expression in tauopathy models
- Synaptic gene dysregulation: BRD4 redistribution in AD neurons leads to loss of BRD4 at synaptic gene super-enhancers and gain at stress-response and inflammatory loci
- BRD4 inhibition is neuroprotective: BET inhibitors (JQ1, I-BET858) reduce neuroinflammation, amyloid plaque burden, and cognitive decline in AD mouse models
In PD, BRD4 contributes to neurodegeneration through:
- Amplification of α-synuclein-induced microglial inflammation via NF-κB coactivation
- Epigenetic dysregulation in dopaminergic neurons — BRD4 mislocalization alters expression of dopaminergic identity genes (TH, NURR1)
- BET inhibitors (JQ1) attenuate MPTP-induced dopaminergic neuronal death and microglial activation in PD models
- BRD4 regulates LRRK2 expression; gain-of-function LRRK2 mutations alter BRD4-dependent transcription
BRD4 dysfunction is prominent in HD:
- Mutant huntingtin (mHTT) sequesters BRD4 into intranuclear inclusions, depleting it from active chromatin
- BRD4 depletion disrupts super-enhancer-driven transcription of striatal identity genes, contributing to medium spiny neuron vulnerability
- BET inhibitors paradoxically improve HD phenotypes by redistributing remaining BRD4 to critical gene loci
BRD4 drives neuroinflammation in ALS spinal cord:
- Microglia in ALS tissue show elevated BRD4 binding at inflammatory gene promoters
- BET inhibitors reduce motor neuron degeneration in SOD1-G93A mouse models
- TDP-43 and FUS pathology alter BRD4-dependent RNA processing
BRD4 is ubiquitously expressed but shows dynamic regulation in the brain:
- Cortical neurons — Constitutive expression; rapidly redistributes to activity-dependent gene loci upon neuronal stimulation
- Microglia — Low basal expression; dramatically upregulated upon activation (LPS, Aβ, α-synuclein)
- Astrocytes — Moderate expression; increases during reactive astrogliosis
- Hippocampus — High expression in CA1 pyramidal neurons; required for spatial learning and memory consolidation
- Striatum — Medium spiny neurons show high BRD4 occupancy at super-enhancers for striatal identity genes
- Substantia nigra — Expressed in dopaminergic neurons and surrounding glia
BRD4 expression and chromatin binding are dynamically regulated by neuronal activity, stress, and inflammatory signals. The short isoform (BRD4-S) and long isoform (BRD4-L) have distinct functions, with BRD4-L containing the C-terminal P-TEFb interaction domain essential for transcriptional elongation.
¶ Common Variants and Risk Alleles
| Variant |
Type |
Association |
Effect |
| rs4808278 |
Intronic |
Neuroinflammatory susceptibility |
Altered BRD4 expression |
| rs2304620 |
5' UTR |
AD risk (suggestive) |
Modified BRD4 translation efficiency |
| rs1062966 |
3' UTR |
Inflammatory gene regulation |
Altered miRNA binding site |
BRD4 has emerged as one of the most promising epigenetic drug targets for neurodegenerative diseases:
- JQ1: Prototype BET bromodomain inhibitor; potent anti-inflammatory effects in AD and PD models. Crosses the blood-brain barrier. Reduces Aβ plaque burden, tau phosphorylation, and microglial activation. However, pan-BET inhibition causes side effects including thrombocytopenia
- I-BET858: Selective BET inhibitor with improved pharmacokinetics; shows efficacy in AD mouse models with reduced peripheral side effects
- ABBV-744 (BD2-selective): Selectively inhibits the second bromodomain of BET proteins, potentially dissociating anti-inflammatory effects from transcriptional toxicity
- BRD4 PROTACs (dBET1, ARV-825): Targeted protein degradation of BRD4; potent anti-inflammatory effects but require careful dosing to avoid neuronal transcriptional collapse
- CPI-0610 (pelabresib): Clinical-stage BET inhibitor with potential neurological applications
- Combination strategies: BRD4 inhibition combined with HDAC inhibitors or anti-amyloid therapy may achieve synergistic neuroprotection